Tides Express | AusperBio Announces Phase IIa Follow-up Data of AHB-137, an ASO-based Investigational Therapy for Chronic Hepatitis B

72Weekly Follow-up (EOF) Main findings:

• Highly Effective Monotherapy

At baselineHBsAgFor100-1,000 IU/mLof patients,30%The subject achieved clinical cure (HBsAg <0.05 IU/mL And HBV DNA< LLOQ), and in225 mgAnd300 mgThe results were consistent in both dose groups. For the baselineHBsAgHigher (1,00–3,000 IU/mL) patients,AHB-137The clinical cure rate is13%（225 mg) and19%（300 mg）。

•AllPersistent Viral Replication Suppression After Drug Discontinuation

CompletedAHB-137After treatment and discontinuation of nucleos(t)ide analogs,100%Patients in24Maintain within the weekHBV DNANegative, showingAHB-137The treatment has a lasting effect on suppressing viral replication.

• Durable complete response after discontinuation of all medications

CompletedAHB-137After treatment and discontinuation of nucleos(t)ide analogs, At baseline100-1,000 IU/mL And100-3,000 IU/mL In the patients, the combined analysis of the two doses respectively had 89% And 82% Subjects maintained a complete response (HBsAg <0.05 IU/mL And HBV DNA, showing AHB-137 Complete response acquired from treatment NA It has good persistence after discontinuation.

•Good Safety and Tolerability

AHB-137The drug was well-tolerated during the treatment and follow-up periods, with no serious adverse events related to the medication, and no interruptions in treatment. Most adverse events were mild to moderate and occurred during the dosing phase.

AboutAB-10-8002

AB-10-8002 is a multicenter, randomized, open-label Phase II clinical study designed to evaluate the safety and efficacy of 24 weeks of AHB-137 monotherapy in HBeAg-negative chronic hepatitis B (CHB) patients who are on stable nucleos(t)ide analog (NA) therapy. Participants receive 24 weeks of AHB-137 treatment at a dose of 300 mg or 225 mg once weekly (with two loading doses on Day 4 and Day 11). After completing AHB-137 treatment, all patients continue NA therapy for an additional 24 weeks. Subjects meeting the NA discontinuation criteria stop NA treatment at Week 48, as assessed by the investigator, and are followed up until Week 72.

AboutAHB-137

AHB-137 is a novel non-conjugated ASO drug developed by AusperBio based on its proprietary Med-Oligo™ antisense oligonucleotide technology platform and is currently being investigated as an experimental therapy.Aiming to achieve clinical cure for chronic hepatitis B. The drug has a triple mechanism of action and has shown positive results in both preclinical and clinical trials, with related outcomes published at prestigious international conferences such as EASL (2023-2025), AASLD (2024-2025), and APASL 2025. AHB-137 has completed global Phase I clinical trials and is currently advancing multiple global Phase II clinical trials alongside Phase III clinical trials in China.

AboutAusperBio

AusperBio, a clinical-stage innovative drug development company operating simultaneously in China and the United States, focuses on developing proprietary targeted delivery small nucleic acid drugs with First-in-class and Best-in-class potential. The company owns the fully proprietary Med-Oligo™ ASO technology platform, primarily concentrating on the functional cure of chronic hepatitis B (HBV) and highly efficient targeted therapies for liver diseases, while actively expanding into new target areas beyond the liver. AusperBio’s strategy is to combine its globally leading Med-Oligo™ oligonucleotide technology with a specifically efficient targeted delivery platform to drive the development of a series of innovative therapies, addressing significant unmet medical needs.